AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31247584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-modal training (combined visual and kinesthetic information)
Number of subjects: 30
Study 29561515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (0.2-0.4 mg/kg) coadministered with amikacin (15 mg/kg)
Number of subjects: 12
Study 29561515 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (15 mg/kg) without lidocaine
Number of subjects: 12
Study 27803922 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal
Number of subjects: 28
Study 27803922 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 28
Study 27803922 — intervention group
Group type: COMPARATOR
Intervention: Intact control group
Number of subjects: 28
Study 25454409 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-item craving scale administered weekly
Number of subjects: 0
Study 25454409 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving assessment including urges, cue-induced craving, and perceived likelihood of relapse
Number of subjects: 0
Study 22702067 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues pre-treatment before laparoscopic myomectomy (LM)
Number of subjects: 212
Study 22702067 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogues pre-treatment before open laparotomic myomectomy (OM)
Number of subjects: 212
Study 22702067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-treatment) for laparoscopic myomectomy (LM)
Number of subjects: 212
Study 22702067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application) for open laparotomic myomectomy (OM)
Number of subjects: 212
Study 20580216 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 microg twice-daily plus Tiotropium 18 microg once-daily (FOR-TIO)
Number of subjects: 33
Study 20580216 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate 12 microg twice-daily plus placebo (FOR-PLA)
Number of subjects: 33
Study 17854302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with β-thalassaemia
Number of subjects: 0
Study 17854302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sickle cell anaemia (SCA)
Number of subjects: 0
Study 17854302 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal phospholipid membrane asymmetry in red blood cells
Number of subjects: 0
Study 16223967 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day)
Number of subjects: 517
Study 16223967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 517
Study 16223967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study 12812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-investigator measurements using contour ROI
Number of subjects: 30
Study 12812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-investigator measurements using contour ROI
Number of subjects: 30
Study 12812432 — intervention group
Group type: EXPERIMENTAL
Intervention: All ROIs
Number of subjects: 30
Study 12812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Contour ROI
Number of subjects: 30
Study 12812432 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 30
Study 10327085 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 cm viewing distance
Number of subjects: 24
Study 10327085 — intervention group
Group type: COMPARATOR
Intervention: 60 cm viewing distance
Number of subjects: 24
Study 9121622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) as add‐on therapy to standard antidepressive medication
Number of subjects: 24
Study 9121622 — intervention group
Group type: COMPARATOR
Intervention: Standard antidepressive medication only
Number of subjects: 24
Study 1707797 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to refrain from blinking
Number of subjects: 0
Study 1707797 — intervention group
Group type: COMPARATOR
Intervention: No instruction to refrain from blinking (Control)
Number of subjects: 0
Study 7117166 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of 5‐isosorbide mononitrate (5‐ISMN)
Number of subjects: 31
Study 7117166 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of 5‐isosorbide mononitrate (5‐ISMN)
Number of subjects: 31
Study 7117166 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of 5‐isosorbide mononitrate (5‐ISMN) three times daily for four weeks
Number of subjects: 31
Study 7117166 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of high doses of 5‐ISMN
Number of subjects: 31
Study 29808615 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective image-scoring system for pulsed-wave Doppler measurement
Number of subjects: 120
Study 29808615 — intervention group
Group type: COMPARATOR
Intervention: Subjective assessment of Doppler images
Number of subjects: 120
Study 29808615 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective scoring system components
Number of subjects: 120
Study 28509813 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel (100 mg, 2 capsules per day for 8 weeks)
Number of subjects: 90
Study 28509813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules per day for 8 weeks)
Number of subjects: 90
Study 25975205 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable dose warfarin (target INR 2.0-2.5), treated for 28 ± 2 days
Number of subjects: 36
Study 25975205 — intervention group
Group type: COMPARATOR
Intervention: Fixed low-dose warfarin (1 mg daily starting 7 days preoperatively), treated for 28 ± 2 days
Number of subjects: 36
Study 25975205 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg daily starting on the day of surgery), treated for 28 ± 2 days
Number of subjects: 36
Study 24190687 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided strength training program (twice weekly for 19 weeks)
Number of subjects: 102
Study 24190687 — intervention group
Group type: COMPARATOR
Intervention: Physical education classes
Number of subjects: 102
Study 24190687 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided strength training program
Number of subjects: 102
Study 21285171 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg eow
Number of subjects: 457
Study 21285171 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg weekly
Number of subjects: 457
Study 21285171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 21285171 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (combined data)
Number of subjects: 457
Study 19685072 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise to determine peak oxygen consumption (V(O)(2peak))
Number of subjects: 18
Study 19685072 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady state exercise at 50% of V(O)(2peak)
Number of subjects: 18
Study 19685072 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady state exercise at 60% of V(O)(2peak)
Number of subjects: 18
Study 18024668 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study 18024668 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 0
Study 18024668 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 15156251 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Aescin + essential phospholipids (AEPL) gel applied for 2 weeks, three times daily
Number of subjects: 10
Study 10802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Light smoking
Number of subjects: 1146
Study 10802843 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking
Number of subjects: 1146
Study 10802843 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 1146
Study 8873362 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 22
Study 8873362 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (control)
Number of subjects: 22
Study 2060547 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.d.
Number of subjects: 7
Study 2060547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6227781 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 6227781 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 0
Study 30715153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw
Number of subjects: 655
Study 30715153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (second course)
Number of subjects: 655
Study 30715153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study 29378603 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional radiotherapy (RT)
Number of subjects: 27
Study 29378603 — intervention group
Group type: COMPARATOR
Intervention: Non-radiotherapy (non-RT)
Number of subjects: 27
Study 29378603 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy following ESD
Number of subjects: 27
Study 29378603 — intervention group
Group type: COMPARATOR
Intervention: Overall survival and cause-specific survival
Number of subjects: 27
Study 26564676 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strengthening exercises (5 exercises, 4 days/week for 12 weeks)
Number of subjects: 12
Study 26564676 — intervention group
Group type: COMPARATOR
Intervention: Regular exercise regimen (control group)
Number of subjects: 12
Study 22281376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick-view reading mode
Number of subjects: 106
Study 22281376 — intervention group
Group type: COMPARATOR
Intervention: Initial reading
Number of subjects: 106
Study 20627022 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 1 mg/kg intravenous 15 minutes before induction of general anesthesia (Group B)
Number of subjects: 60
Study 20627022 — intervention group
Group type: COMPARATOR
Intervention: No premedication (Group A)
Number of subjects: 60
Study 18343243 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR methylphenidate 20 mg QD
Number of subjects: 21
Study 18343243 — intervention group
Group type: COMPARATOR
Intervention: OROS methylphenidate 18 mg QD
Number of subjects: 21
Study 15841929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 100 microg every 2 hours
Number of subjects: 153
Study 15841929 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg every 4 hours
Number of subjects: 153
Study 15841929 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol 100 microg every 2 hours
Number of subjects: 153
Study 12109627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of oral 17beta E2 daily (group A)
Number of subjects: 43
Study 12109627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2 daily plus 5 mg daily oral dydrogesterone (group B)
Number of subjects: 43
Study 12109627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2 and 10 mg dydrogesterone (group C)
Number of subjects: 43
Study 12109627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10674879 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, epirubicin 30 mg m(‐2) i.v. days 1 and 8)
Number of subjects: 151
Study 10674879 — intervention group
Group type: COMPARATOR
Intervention: CNF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, mitoxantrone 6 mg m(‐2) i.v. days 1 and 8)
Number of subjects: 151
Study 10674879 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 151
Study 10674879 — intervention group
Group type: COMPARATOR
Intervention: CNF
Number of subjects: 151
Study 9499814 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge after beta 2‐agonist pre‐treatment
Number of subjects: 10
Study 9499814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial histamine and methacholine challenges (HiCh/MeCh)
Number of subjects: 10
Study 9499814 — intervention group
Group type: COMPARATOR
Intervention: Bronchial challenges (HiCh/MeCh)
Number of subjects: 10
Study 1870041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypodermoclysis with hyaluronidase (250 U)
Number of subjects: 12
Study 1870041 — intervention group
Group type: COMPARATOR
Intervention: Hypodermoclysis without hyaluronidase
Number of subjects: 12
Study 6467496 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonantradol
Number of subjects: 57
Study 6467496 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 57
Study 31464392 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient pack
Number of subjects: 49
Study 29051325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 4 weeks (2q4)
Number of subjects: 748
Study 29051325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 8 weeks after five initial monthly doses (2q8)
Number of subjects: 748
Study 29051325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2q4 and 2q8 pooled)
Number of subjects: 748
Study 29051325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 748
Study 29051325 — intervention group
Group type: COMPARATOR
Intervention: Macular laser photocoagulation
Number of subjects: 748
Study 26687984 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331
Study 26687984 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy without exercise training (Control)
Number of subjects: 2331
Study 25249397 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus adalimumab (DMARD + ADA)
Number of subjects: 76
Study 25249397 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus placebo (DMARD)
Number of subjects: 76
Study 25249397 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline CXCL13 levels
Number of subjects: 76
Study 25249397 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL13 plasma levels
Number of subjects: 76
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 20 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 10 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 5 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 2.5 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride concentration at 0 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk at 60°C
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk at 22°C
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk at 4°C
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 20 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 10 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 5 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 2.5 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 0 mg/l
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 60°C
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 22°C
Number of subjects: 126
Study 22706204 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel fluoride uptake (EFU) at 4°C
Number of subjects: 126
Study 20844179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-platform design (mobile-bearing)
Number of subjects: 273
Study 20844179 — intervention group
Group type: COMPARATOR
Intervention: All-polyethylene tibial component (fixed-bearing)
Number of subjects: 273
Study 16988647 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g xylitol in water
Number of subjects: 70
Study 16988647 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g xylitol in water
Number of subjects: 70
Study 16988647 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g erythritol in water
Number of subjects: 70
Study 16988647 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g erythritol in water
Number of subjects: 70
Study 16988647 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g erythritol in water
Number of subjects: 70
Study 16988647 — intervention group
Group type: COMPARATOR
Intervention: 45 g sucrose
Number of subjects: 70
Study 16988647 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of xylitol and erythritol
Number of subjects: 70
Study 18003959 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg once daily)
Number of subjects: 428
Study 18003959 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (10 mg once daily)
Number of subjects: 428
Study 15286097 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg as a single oral dose
Number of subjects: 16
Study 15286097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg twice daily for 5 days plus a 40 mg oral dose of atorvastatin on day 4
Number of subjects: 16
Study 10772054 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Hall tilting disc valve (MH)
Number of subjects: 24
Study 10772054 — intervention group
Group type: COMPARATOR
Intervention: St. Jude Medical bileaflet valve (SJM)
Number of subjects: 24
Study 9069575 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg i.v. ondansetron
Number of subjects: 40
Study 9069575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 8260695 — intervention group
Group type: EXPERIMENTAL
Intervention: EVDAC regimen (high-dose epirubicin, vincristine, dexamethasone, followed by cyclophosphamide and high-dose cytarabine)
Number of subjects: 54
Study 8260695 — intervention group
Group type: EXPERIMENTAL
Intervention: EVDAC regimen
Number of subjects: 54
Study 2408848 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EMG activity variations
Number of subjects: 4
Study 2408848 — intervention group
Group type: EXPERIMENTAL
Intervention: Median nerve stimulus voltages
Number of subjects: 4
Study 2408848 — intervention group
Group type: EXPERIMENTAL
Intervention: H/M ratio less than 50%
Number of subjects: 4
Study 995040 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg one hour before lunch)
Number of subjects: 25
Study 995040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31251679 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign Language (FL) learning
Number of subjects: 0
Study 31251679 — intervention group
Group type: EXPERIMENTAL
Intervention: Games
Number of subjects: 0
Study 31251679 — intervention group
Group type: COMPARATOR
Intervention: Music appreciation
Number of subjects: 0
Study 29972516 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Operating Procedure (SOP)
Number of subjects: 30
Study 29972516 — intervention group
Group type: COMPARATOR
Intervention: Unit Routine Decubitus (URD)
Number of subjects: 30
Study 26031908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis (BB‐12(®)) at a dose of 10(9) CFU
Number of subjects: 210
Study 26031908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24923723 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week hemifield eye patching and daily sessions of optokinetic stimulation (n=11)
Number of subjects: 21
Study 24923723 — intervention group
Group type: COMPARATOR
Intervention: No neglect-specific treatment (n=10)
Number of subjects: 21
Study 22722637 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal Fufang (10 g/day, twice per day, n = 101)
Number of subjects: 194
Study 22722637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 93)
Number of subjects: 194
Study 22722637 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal Fufang (n = 101)
Number of subjects: 194
Study 20842051 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG loaded virus-like nanoparticles vaccine
Number of subjects: 22
Study 17508528 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic medications
Number of subjects: 0
Study 17508528 — intervention group
Group type: COMPARATOR
Intervention: No treatment (normal neurologic examination, normal test results, no structural brain disease)
Number of subjects: 0
Study 16095588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to ambiguous pronunciation followed by immediate testing
Number of subjects: 0
Study 16095588 — intervention group
Group type: COMPARATOR
Intervention: Exposure to Same or Different speaker for 25 min with no relevant input
Number of subjects: 0
Study 16095588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Same or Different speaker for 25 min with one relevant input
Number of subjects: 0
Study 16095588 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to Same or Different speaker for 25 min with both relevant inputs
Number of subjects: 0
Study 12153606 — intervention group
Group type: EXPERIMENTAL
Intervention: Good metabolic control (HbA1c < or = 7.0)
Number of subjects: 40
Study 12153606 — intervention group
Group type: COMPARATOR
Intervention: Poor metabolic control (HbA1c > or = 8.0)
Number of subjects: 40
Study 12153606 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of basal plasma C‐peptide
Number of subjects: 40
Study 12153606 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of auc C‐peptide
Number of subjects: 40
Study 12153606 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analyses
Number of subjects: 40
Study 10455090 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Peak Power (SPP) measured at rest and during maximum exercise
Number of subjects: 40